Whats In A Name? How the Functional Title Encompasses the MSL Role

Ryan McGuire, lifecycle management tactics expert
By Ryan McGuire,
Research Analyst

The MSL role should be an easy to define. But if this is truly the case, why does the pharmaceutical industry use so many different titles used to describe the function? Besides medical science liaisons, there are also regional medical liaisons, clinical science liaisons and regional scientific liaisons.  Independent of their actual title, they all perform the same essential duties — bridging the gap between pharmaceutical companies and the medical community.  On the surface, the definition of an MSL is quite logical; however, once you take into account all of the typical responsibilities, the MSL role begins to look quite complex. Continue reading


Are You Ready to Optimize Your Medical Publications Department?

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Within the life sciences industry, medical publications groups are tasked with a critical responsibility: sharing company findings and new scientific brand support details with the healthcare community.  To ensure that these key medical communications groups are working efficiently, companies should provide them with the resources needed to meet demands.  Whether teams are responsible for 5 or 500 publications per year, companies should right-size the staffing and budgets allocated to these efforts.  They should also consider company structure. Cutting Edge Informations recent study on medical publications departments highlights how top-performing pharmaceutical and device organizations resource and measure performance across various high- and low-output team structures. Continue reading



Developing Pharma Key Opinion Leaders Requires a Personal Touch

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

At a recent conference I attended focused on pharma advisory boards, one of the presentations focused on KOL relationships and best practices for maintaining effective contact with thought leaders.  One of the key takeaways for me in terms of pharma key opinion leaders was the need to ensure that there is a personal touch to communications.  This corroborated a lot of what weve seen here in our research at Cutting Edge Information.  Continue reading


Surveyed Companies Reveal Pharmaceutical Ad Board Costs

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

Ad boards and their related costs are a growing area of interest in the life sciences industry. A sampling of companies surveyed by Cutting Edge Information recently reported their spending for an average pharmaceutical ad board conducted in the US. Among surveyed companies, the average multinational clinical ad board convened in the US costs $129,000. A national clinical ad board in the US costs these same companies an average of $78,000 while a local ad board costs an average of $36,000. Continue reading


The Value of Medical Affairs Lies in Its Ties to Patient Care

Elio Evangelista, physician fair-market value expert
By Elio Evangelista,
Senior Director

A theme that emerged at World Congress Second Annual Summit on The Evolving Role of Medical Affairs and Thought Leader Engagement in an Era of Transparency, held in Philadelphia from May 20 to 21, is that medical affairs teams face universal challenges — regardless of whether theyre housed within large Top 50 drug makers, small specialty biotechs or medical device companies. The greatest challenge to these teams is not necessarily the effects of new transparency regulations, but rather, the same internal obstacle that these teams have faced for decades: how to prove their value to senior leadership.

The presentations delivered by some of the industrys most experienced medical affairs leaders highlighted several key themes that underscore common challenges Continue reading


KOL Management for Small Pharma Leans Heavily on Existing Networks Within Companies

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When it comes to managing and nurturing thought leader relationships and specifically the process of identifying key opinion leaders, companies have several options. Many choose to outsource the identification process and contact KOLs once theyve been identified by the third-party vendor. For larger and mid-sized companies that are looking to expand into new therapeutic areas or geographic regions, vendors provide an extremely valuable and effective service. Continue reading


Pharmaceutical Digital Marketing: Establishing Pharma as an Invaluable Information Resource

Eric Bolesh, commercialization and alliance management expert
By Eric Bolesh,
Senior Director

Over the years, pharmaceutical companies digital marketing activities have enabled them to adopt a different approach to reaching patients, caregivers and physicians alike. Beyond direct-to-consumer television ads and email sends, many organizations have branched out to incorporate new channels within their existing marketing strategies. To be certain, the pharmaceutical industry has developed a number of innovative branded and unbranded solutions using a multitude of platforms. For example, companies have launched Facebook pages, Twitter accounts and YouTube channels geared toward specific audiences as a means to generate campaign awareness and promote consumer education. However, with the growth of the technological age and digital capabilities, correcting misinformation can be just as much of a challenge as disseminating company and product information. Continue reading


Making the Most of Scientific Advisory Boards with Clear Objectives

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When bringing together a group of active clinicians and specialists for a scientific advisory board, companies should make sure to maximize the effectiveness of the resources seated around the table.  Each person in the room has a different set of experiences, all of which are invaluable to the clinical trial being discussed. The process of converting this aggregated knowledge into a better product is what differentiates an average advisory board from a truly successful one. Continue reading


Looking Outside the Box: How Medical Communications Groups Engage the Medical Community

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

As the life sciences industry grows, companies internal groups must also evolve to match changing demands.  One surveyed pharmaceutical executive explained, “By and large, companies seem to know that consumers want more face time with organizations at a gut level, and companies are moving along that path.”  In response to this movement, medical communications teams are experiencing increasing visibility within both medical affairs and life science companies at large. Continue reading